PCSK9 and cardiovascular disorder: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab in ODYSSEY OUTCOME (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trials, respectively, reduced MACE when added to statin therapy in patients with cardiovascular disease (24, 25).